Supplementary Table S1. Cox univariable and multivariable analyses under the condition of overall survival probability in association with IMPA2/mTORC1 geneset mRNA expression levels and pathological stage derived TCGA cohort with clear-cell renal cell carcinoma.

| Overall Survival ( $n=493$ ) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Variables | Univariable (HR, 95\%CI) | $P$ | Multivariable <br> (HR, 95\%CI) | $P$ |
| Age |  |  |  |  |
| $<60$ | 1 | NA | 1 | NA |
| $\geq 60$ | 1.76 (1.29-2.40) | <0.001 | 1.66 (1.21-2.28) | 0.002 |
| gender |  |  |  |  |
| female | 1 | NA | 1 | NA |
| male | 0.94 (0.69-1.28) | 0.690 | 0.81 (0.58-1.12) | 0.207 |
| pT |  |  |  |  |
| T1-T2 | 1 | NA | 1 | NA |
| T3-T4 | 3.02 (2.22-4.11) | <0.001 | 0.51 (0.43-1.53) | 0.516 |
| pM |  |  |  |  |
| M0 | 1 | NA | 1 | NA |
| M1 | 4.27 (3.12-5.83) | <0.001 | 2.28 (1.54-3.38) | <0.001 |
| stage |  |  |  |  |
| I-II | 1 | NA | 1 | NA |
| III-IV | 3.62 (2.64-4.99) | <0.001 | 2.31 (1.12-4.76) | 0.023 |
| grade |  |  |  |  |
| I-II | 1 | NA | 1 | NA |
| III-IV | 2.57 (1.83-3.61) | <0.001 | 1.50 (1.03-2.18) | 0.034 |
| IMPA2 levels |  |  |  |  |
| High | 1 | NA | 1 | NA |
| Low | 2.02 (1.48-2.77) | <0.001 | 1.54 (1.09-2.16) | 0.014 |
| mTORC1 levels |  |  |  |  |
| Low | 1 | NA | 1 | NA |
| High | 1.83 (1.34-2.49) | <0.001 | 1.33 (0.96-1.85) | 0.085 |
| IMPA2/mTROC1 levels |  |  |  |  |
| High/Low | 1 | NA | 1 | NA |
| Low/High | 3.06 (2.00-4.68) | $<0.001$ | 1.10 (0.79-1.52) | 0.578 |

HR and CI denote hazard ratio and confident interval, respectively.

Supplementary Table S2. The relationship between IMPA2/mTORC1 geneset levels and the clinicopathological characteristics of TCGA cohort with clear cell renal cell carcinoma.

| Clinicopathological Characteristics | $n$ | IMPA2/mTORC1 Geneset Levels, $n(\%)$ |  |  | $P^{a}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | High/Low $(n=143)$ | $\begin{aligned} & \text { Others } \\ & (n=208) \end{aligned}$ | Low/High $(n=142)$ |  |
| Age |  |  |  |  |  |
| <60 | 244 | 72(29.5\%) | 105(43.0\%) | 67(27.5\%) |  |
| $\geq 60$ | 249 | 71(28.5\%) | 103(41.4\%) | 75(30.1\%) | 0.808 |
| gender |  |  |  |  |  |
| female | 168 | 70(41.7\%) | 64(38.1\%) | 34(20.2\%) |  |
| male | 325 | 73(22.5\%) | 144(44.3\%) | 108(33.2\%) | $<0.001$ |
| pT |  |  |  |  |  |
| T1-T2 | 308 | 109(35.4\%) | 133(43.2\%) | 66(21.4\%) |  |
| T3-T4 | 185 | 34(18.4\%) | 75(40.5\%) | 76(41.1\%) | $<0.001$ |
| pM ( ${ }^{\text {c }}$ |  |  |  |  |  |
| M0 | 415 | 132(31.8\%) | 178(42.9\%) | 105(25.3\%) |  |
| M1 | $78$ | 11(14.1\%) | 30(38.5\%) | 37(47.4\%) | $<0.001$ |
| stage |  |  |  |  |  |
| I-II | 291 | 105(36.1\%) | 123(42.3\%) | 63(21.6\%) |  |
| III-IV | 202 | 38(18.8\%) | 85(42.1\%) | 79(39.1\%) | <0.001 |
| grade |  |  |  |  |  |
| G1-G2 | 224 | 86(38.4\%) | 100(44.6\%) | 38(17.0\%) |  |
| G3-G4 | 269 | 57(21.2\%) | 108(40.1\%) | 104(38.7\%) | $<0.001$ |

${ }^{\text {a }} P$ values were derived with a two-sided Pearson chi-square test.

